The National Comprehensive Cancer Network and NCCN Member Institutions

April 2012 Vol 3, No 2
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Co-Founder, AONN+; Editor, JONS; University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Developer, Work Stride-Managing Cancer at Work, Johns Hopkins Healthcare Solutions

The National Comprehensive Cancer Network® (NCCN®) is a nonprofit alliance of 21 of the world’s leading cancer centers. With the contributions of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to members of the healthcare system. As an arbiter of high-quality cancer care, the NCCN promotes continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other healthcare decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

Each year at NCCN Member Institutions, more than 160,000 new patients receive cancer care from world-renowned experts who are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and continue to integrate programs in patient care, research, and education. Forty-one Nobel Prize winners have served on the faculties of NCCN Member Institutions.

There is a wealth of information on NCCN’s Web site for healthcare professionals (www. nccn.org), including screening criteria, surveillance guidelines, and treatment guidelines that have now been expanded to include survivorship care guidelines. There is also a specific Web site for patients (www.nccn.com) that provides a listing of the Member Institutions and information in layman’s terms that helps patients understand the phases of treatment and what they might expect as they embark on their own cancer care.

Related Items

Updates to NCCN Guidelines for Multiple Myeloma: Recently Approved First-Line Treatments for Patients With NDMM Eligible and Ineligible for Transplant
Web Exclusives
Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.
JONS Editor-in-Chief: Passing the Baton
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
June 2023 Vol 14, No 6
Dear Navigators, Social Workers, Administrators, and Clinical Staff, With this letter, I want to share some news with you.
National Nurses Month: Celebrating the Impact of Nurses
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
May 2023 Vol 14, No 5
All day, every day, nurses make all the difference in delivering high-quality care to those who need it the most. On behalf of all of us at AONN+, I want to recognize the nurses in our community for their invaluable contributions to healthcare.
Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country